Stoke Therapeutics (NASDAQ:STOK) Coverage Initiated at Leerink Partners

Leerink Partners started coverage on shares of Stoke Therapeutics (NASDAQ:STOKFree Report) in a research report released on Monday, StockNewsAPI reports. The firm issued an outperform rating and a $18.00 target price on the stock.

Several other equities analysts have also issued reports on STOK. HC Wainwright reissued a buy rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Wedbush reissued an outperform rating and issued a $17.00 price target on shares of Stoke Therapeutics in a report on Thursday, July 11th. Finally, Needham & Company LLC reissued a buy rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics currently has an average rating of Moderate Buy and an average target price of $20.83.

Read Our Latest Stock Report on Stoke Therapeutics

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $12.76 on Monday. The firm has a fifty day moving average of $13.78 and a two-hundred day moving average of $13.71. The stock has a market capitalization of $665.06 million, a price-to-earnings ratio of -5.29 and a beta of 0.97. Stoke Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOKGet Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.11. The company had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. As a group, research analysts forecast that Stoke Therapeutics will post -2.1 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Redmile Group LLC grew its stake in Stoke Therapeutics by 93.2% during the first quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after purchasing an additional 2,447,543 shares during the period. Lynx1 Capital Management LP lifted its holdings in shares of Stoke Therapeutics by 40.3% in the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Stoke Therapeutics during the second quarter valued at approximately $19,835,000. Baker BROS. Advisors LP increased its position in shares of Stoke Therapeutics by 65.9% during the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock valued at $45,474,000 after acquiring an additional 1,338,309 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter.

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Further Reading

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.